XML 123 R107.htm IDEA: XBRL DOCUMENT v3.10.0.1
Supplementary Quarterly Financial Data (Unaudited) - Schedule of Quarterly Financial Data (Detail) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
 3 Months Ended 12 Months Ended
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2015
Total revenue $ 200.9 $ 191.1 $ 192.7 $ 187.9 $ 199.6 $ 194.7 $ 196.7 $ 178.9 $ 772.6 $ 769.9 $ 740.5 $ 722.5
Costs and expenses:                        
Research and development expense 17.7 18.5 16.8 17.8 18.8 17.6 18.6 19.4 70.8 74.4 70.6 75.5
Change in the fair value of contingent consideration 0.2 (1.2) 13.0 (73.2) (2.7) 5.2 (3.8) 0.5 (61.2) (0.8)    
Selling, general, and administrative expense 121.4 115.1 115.4 115.2 122.1 122.1 120.3 111.9 467.1 476.4 359.2 366.0
Total costs and expenses 185.0 176.5 189.6 102.8 180.7 189.2 179.5 171.8 653.9 721.2 587.1 588.9
Operating income 15.9 14.6 3.1 85.1 18.9 5.5 17.2 7.1 118.7 48.7 153.4 133.6
Other income (expense):                        
Interest income 0.5 0.5 0.4 0.4 0.3 0.3 0.3 0.3 1.8 1.2 0.9 0.4
Interest expense (1.1) (0.5) (0.7) (0.9) (1.2) (1.5) (2.6) (0.7) (3.2) (6.0) (0.3) (0.2)
Other 0.8 (0.5) (0.4) (0.3) (0.1) 1.5 (2.6) (1.8) (0.4) (3.0) 2.0 0.5
Total other income (expense): 0.2 (0.5) (0.7) (0.8) (1.0) 0.3 (4.9) (2.2) (1.8) (7.8) 2.6 0.7
Income before income tax 16.1 14.1 2.4 84.3 17.9 5.8 12.3 4.9 116.9 40.9 156.0 134.3
Income tax provision 3.0 4.5 (26.3) 4.8 5.8 3.0 6.2 5.6 (14.0) 20.6 38.8 54.5
Net income 13.1 9.6 28.7 79.5 12.1 2.8 6.1 (0.7) 130.9 20.3 117.2 79.8
Net loss attributable to non-controlling interest   (0.1)   (0.1) (0.2)       (0.2) (0.2)    
Net income attributable to Myriad Genetics, Inc. stockholders $ 13.1 $ 9.7 $ 28.7 $ 79.6 $ 12.3 $ 2.8 $ 6.1 $ (0.7) $ 131.1 $ 20.5 $ 117.2 $ 79.8
Earnings per share:                        
Basic $ 0.19 $ 0.14 $ 0.41 $ 1.16 $ 0.18 $ 0.04 $ 0.09 $ (0.01) $ 1.89 $ 0.30 $ 1.67 $ 1.12
Diluted $ 0.18 $ 0.13 $ 0.40 $ 1.13 $ 0.18 $ 0.04 $ 0.09 $ (0.01) $ 1.82 $ 0.30 $ 1.60 $ 1.07
Weighted average shares outstanding:                        
Basic 70.1 69.8 69.3 68.6 68.2 68.1 68.2 68.8 69.4 68.3 70.0 71.3
Diluted 72.9 72.4 71.9 70.4 68.9 68.3 68.3 68.8 72.0 68.8 73.4 74.5
Molecular Diagnostic Testing [Member]                        
Total revenue $ 187.6 $ 177.3 $ 177.9 $ 176.5 $ 187.0 $ 183.0 $ 184.1 $ 166.5 $ 719.3 $ 720.6 $ 692.4 $ 694.9
Costs and expenses:                        
Total costs and expenses 38.0 36.8 37.7 36.2 35.6 37.9 37.4 34.3 148.7 145.2 132.8 132.8
Pharmaceutical and Clinical Services [Member]                        
Total revenue 13.3 13.8 14.8 11.4 12.6 11.7 12.6 12.4 53.3 49.3 48.1 27.6
Costs and expenses:                        
Total costs and expenses $ 7.7 $ 7.3 $ 6.7 $ 6.8 $ 6.9 $ 6.4 $ 7.0 $ 5.7 $ 28.5 $ 26.0 $ 24.5 $ 14.6